OB/GYN News - Abraxane approved
April 1, 2005 -- Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) has been approved for the treatment...
Internal Medicine News - Abraxane approved
April 1, 2005 -- Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) has been approved for the treatment...
Business Wire - Abraxis BioScience Launches Abraxane® in European Union
December 15, 2008 -- Initial Product Launch in the UK, Followed by Germany in Q1 2009 LOS ANGELES & LONDON -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully...
Business Wire - Acusphere to Develop Potential Abraxane® Bioequivalent
November 2, 2007 -- Reformulation of paclitaxel offers partnership opportunities and faster track to commercialization WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ:...
Business Wire - ABRAXANE in Combination with Gemcitabine and Epirubicin Evaluated as Neoadjuvant Treatment for Patients with Locally Advanced Breast Cancer
December 13, 2008 -- Interim Data from Phase II Trial Presented at 31st Annual San Antonio Breast Cancer Symposium SAN ANTONIO -- Abraxis BioScience, Inc....
Business Wire - New Data Evaluating ABRAXANE in Early-Stage Breast Cancer and in Combination with Novel Investigational Agents to Be Presented at SABCS
December 10, 2008 -- Results from Five Company-Sponsored Studies Presented at the 31st Annual San Antonio Breast Cancer Symposium SAN ANTONIO -- Abraxis BioScience,...
Business Wire - Abraxis BioScience and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in Australia
October 16, 2008 -- LOS ANGELES & MELBOURNE, Australia -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised...
Business Wire - Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer
July 18, 2008 -- BANGALORE, India, & LOS ANGELES -- Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully...
Business Wire - Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
July 14, 2008 -- Approval of ABRAXANE Based on Pivotal Phase III Randomized Trials in the U.S. and China Company Developing Infrastructure and Alliances in...
Business Wire - New Data Highlighting the Potential Utility of ABRAXANE in Combination with Targeted Therapies and Other Chemotherapeutic Agents to Be Presented at ASCO
May 16, 2008 -- Abraxis to Report Clinical Results from 23 Company and Investigator-Sponsored Studies LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ:ABII), an...
